The first COVID-19 vaccine could arrive before Election Day, Donald Trump avowed in the summer of 2020. But government regulators wanted things to work out differently: “The deep state, or whoever, over at the FDA is making it very difficult for drug companies to get people in order to test the vaccines and therapeutics,” he wrote on Twitter. “Obviously, they are hoping to delay the answer until after November 3rd.
The Delta variant’s arrival this summer delivered a blow to the nation’s entire coronavirus arsenal, but its impact on the champion of last year’s vaccine race—Pfizer—has been particularly humbling. Compared with Moderna’s competing shot, Pfizer’s vaccine seems to induce half the amount of virus-fighting antibodies, and is associated with nearly twice as many breakthrough infections, according to two recent studies.
About a week after Steven Mikac began taking antibiotics for the strange spot on his leg, the flesh around his ankle started to tighten and swell. The moist orifice of a wound opened up and took the form of a small bullet hole. A plug of tissue had gone missing—dissolved into pus and slime. Walking was excruciating. Working, unbearable. In early October of last year, Mikac showed his ankle to a colleague at the hospital where he works in Melbourne, in the Australian state of Victoria.